In patients with EGFR-mutant advanced NSCLC, frontline therapy with EGFR tyrosine kinase inhibitors (TKIs) provides superior clinical outcomes as compared to chemotherapy (3–6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.